Suffolk Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Suffolk Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$8.31M	Buy	230,149 +22,679	+11%	+$1.06M	1.59%	39
2018 Q3	$12.8M	Sell	207,470 -4,058	-2%	-$261K	1.82%	27
2018 Q2	$14.3M	Sell	211,528 -2,717	-1%	-$152K	2.04%	12
2018 Q1	$11.6M	Sell	214,245 -41,204	-16%	-$2.3M	1.65%	26
2017 Q4	$15.3M	Sell	255,449 -28,058	-10%	-$1.7M	1.98%	9
2017 Q3	$13.8M	Buy	283,507 +137,654	+94%	+$7.51M	1.82%	20
2017 Q2	$7.67M	Buy	145,853 +128,760	+753%	+$6M	1.01%	45
2017 Q1	$775K	Sell	17,093 -20,844	-55%	-$930K	0.1%	120
2016 Q4	$1.44M	Buy	37,937 +4,032	+12%	+$152K	0.2%	103
2016 Q3	$1.28M	Sell	33,905 -85,100	-72%	-$1.88M	0.18%	120
2016 Q2	$2.09M	Buy	+119,005	New	+$1.93M	0.27%	114

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Suffolk Capital Management's AERI Position: Q4 2018 in Review

Suffolk Capital Management increased its Aerie Pharmaceuticals (AERI) stake by 11% in Q4 2018, buying an estimated $1.06M and bringing the position to 230,149 shares worth $8.31M. The position accounts for 1.59% of the portfolio, ranked #39.

Suffolk Capital Management first reported a position in AERI in Q2 2016 and has held it in 11 quarters since. The position peaked at $15.3M in Q4 2017. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Suffolk Capital Management held 230,149 shares of Aerie Pharmaceuticals worth $8.31M as of Q4 2018.
Suffolk Capital Management bought 22,679 Aerie Pharmaceuticals shares in Q4 2018, an estimated $1.06M.
Aerie Pharmaceuticals made up 1.59% of Suffolk Capital Management's portfolio in Q4 2018, its #39 holding.
Suffolk Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2016 and has held it in 11 quarters since.
Suffolk Capital Management's Aerie Pharmaceuticals position peaked at $15.3M in Q4 2017.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Suffolk Capital Management's 13F filing for Q4 2018, filed 23 Jan 2019.